{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:13:42Z","timestamp":1790334822096,"version":"4.1.0"},"reference-count":141,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kennedy Trust for Rheumatology Research","award":["20 21 06"],"award-info":[{"award-number":["20 21 06"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Psoriasis is a lifelong, systemic, immune mediated inflammatory skin condition, affecting 1\u20133% of the world\u2019s population, with an impact on quality of life similar to diseases like cancer or diabetes. Genetics are the single largest risk factor in psoriasis, with Genome-Wide Association (GWAS) studies showing that many psoriasis risk genes lie along the IL-23\/Th17 axis. Potential psoriasis risk genes determined through GWAS can be annotated and characterised using functional genomics, allowing the identification of novel drug targets and the repurposing of existing drugs. This review is focused on the IL-23\/Th17 axis, providing an insight into key cell types, cytokines, and intracellular signaling pathways involved. This includes examination of currently available biological treatments, time to relapse post drug withdrawal, and rates of primary\/secondary drug failure, showing the need for greater understanding of the underlying genetic mechanisms of psoriasis and how they can impact treatment. This could allow for patient stratification towards the treatment most likely to reduce the burden of disease for the longest period possible.<\/jats:p>","DOI":"10.3390\/biom14050548","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T03:43:46Z","timestamp":1714707826000},"page":"548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-0576","authenticated-orcid":false,"given":"Elan May","family":"Shellard","sequence":"first","affiliation":[{"name":"Faculty of Biology, Medicine and Health, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Manchester M13 9PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-036X","authenticated-orcid":false,"given":"Shraddha S.","family":"Rane","sequence":"additional","affiliation":[{"name":"Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester M13 9PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Eyre","sequence":"additional","affiliation":[{"name":"Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester M13 9PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester M6 8HD, UK"},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M23 9LT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clindermatol.2006.07.006","article-title":"Psoriasis and psoriatic arthritis: Clinical features and disease mechanisms","volume":"24","author":"Myers","year":"2006","journal-title":"Clin. Dermatol."},{"key":"ref_3","unstructured":"World Health Organization (2016). Global Report on Psoriasis, World Health Organization."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-012-8305-3","article-title":"Clinical and Histologic Diagnostic Guidelines for Psoriasis: A Critical Review","volume":"44","author":"Johnson","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","unstructured":"PCDS PCDS (2022, November 22). Psoriasis: An Overview and Chronic Plaque Psoriasis. Available online: https:\/\/www.pcds.org.uk\/clinical-guidance\/psoriasis-an-overview."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2001.01311.x","article-title":"Fine Mapping of the PSORS4 Psoriasis Susceptibility Region on Chromosome 1q21","volume":"116","author":"Capon","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ng.694","article-title":"A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1","volume":"42","author":"Strange","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/archdermatol.2009.73","article-title":"Psoriasis bench to bedside: Genetics meets immunology","volume":"145","author":"Nair","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jid.2016.11.007","article-title":"Recent Highlights in Psoriasis Research","volume":"137","author":"Hwang","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13555-021-00677-8","article-title":"Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond","volume":"12","author":"Sugiura","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/jid.2015.186","article-title":"Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients","volume":"135","author":"Frambach","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.3389\/fimmu.2018.02167","article-title":"CARD14\/CARMA2 Signaling and its Role in Inflammatory Skin Disorders","volume":"9","author":"Zotti","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 Mutations Cause Skin Autoin-flammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production","volume":"136","author":"Mahil","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2023-8-2","article-title":"Childhood guttate psoriasis: An updated review","volume":"12","author":"Leung","year":"2023","journal-title":"Drugs Context"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/PTT.S101232","article-title":"Erythrodermic psoriasis: Pathophysiology and current treatment perspectives","volume":"6","author":"Liao","year":"2016","journal-title":"Psoriasis: Targets Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jid.2016.12.032","article-title":"Dual Role of Act1 in Keratinocyte Differentiation and Host De-fense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses","volume":"137","author":"Lambert","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","article-title":"CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23\/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo","volume":"138","author":"Mellett","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.immuni.2018.05.012","article-title":"Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A","volume":"49","author":"Wang","year":"2018","journal-title":"Immunity"},{"key":"ref_23","first-page":"1","article-title":"Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_24","first-page":"740","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"Oji","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/npp.2012.73","article-title":"Epigenetics of the Depressed Brain: Role of Histone Acetylation and Methylation","volume":"38","author":"Sun","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1172\/JCI97426","article-title":"MicroRNA-210 overexpression promotes psoriasis-like in-flammation by inducing Th1 and Th17 cell differentiation","volume":"128","author":"Wu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_27","unstructured":"Ray-Jones, H. (2018). Defining the Key Biological and Genetic Mechanisms Involved in Psoriasis. [PhD Thesis, University of Manchester]."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","article-title":"A cross-population atlas of genetic associations for 220 human phenotypes","volume":"53","author":"Sakaue","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jid.2021.02.196","article-title":"176 Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine-mapping in the MHC and genomewide","volume":"141","author":"Stuart","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jid.2019.07.692","article-title":"Exome-Wide Rare Loss-of-Function Variant Enrichment Study of 21,347 Han Chinese Individuals Identifies Four Susceptibility Genes for Psoriasis","volume":"140","author":"Yang","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jid.2017.10.001","article-title":"Variants at HLA-A, HLA-C, and HLA-DQB1 Confer Risk of Psoriasis Vulgaris in Japanese","volume":"138","author":"Hirata","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dand, N., Stuart, P.E., Bowes, J., Ellinghaus, D., Nititham, J., Saklatvala, J.R., Teder-Laving, M., Thomas, L.F., Traks, T., and Uebe, S. (2023). GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. medRxiv.","DOI":"10.1101\/2023.10.04.23296543"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: From keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/hmg\/ddab237","article-title":"A transcriptome-wide association study identifies novel susceptibility genes for psoriasis","volume":"31","author":"Zhu","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jeong, Y., Song, J., Lee, Y., Choi, E., Won, Y., Kim, B., and Jang, W. (2023). A Transcriptome-Wide Analysis of Psoriasis: Identifying the Potential Causal Genes and Drug Candidates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411717"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-020-2188-x","article-title":"A reference map of the human binary protein interactome","volume":"580","author":"Luck","year":"2020","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jid.2020.09.024","article-title":"ELL Facilitates RNA Polymerase II-Mediated Transcription of Human Epi-dermal Proliferation Genes","volume":"141","author":"Li","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1128\/MCB.01674-12","article-title":"C\/EBP\u03b3 Suppresses Senescence and Inflammatory Gene Expression by Heterodimerizing with C\/EBP\u03b2","volume":"33","author":"Huggins","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Human. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.ejhg.5201755","article-title":"Methods for the selection of tagging SNPs: A comparison of tagging efficiency and performance","volume":"15","author":"Ding","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1038\/ncomms7793","article-title":"Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis","volume":"6","author":"Zuo","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jid.2015.11.025","article-title":"One SNP at a Time: Moving beyond GWAS in Psoriasis","volume":"136","author":"Eyre","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Filkor, K., Heged\u0171s, Z., Sz\u00e1sz, A., Tubak, V., Kem\u00e9ny, L., Kondorosi, \u00c9., and Nagy, I. (2013). Genome Wide Transcriptome Analysis of Dendritic Cells Identifies Genes with Altered Expression in Psoriasis. PLOS ONE, 8.","DOI":"10.1371\/journal.pone.0073435"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/jid.2011.267","article-title":"Transcriptional Profiling of Psoriasis Using RNA-seq Reveals Previously Unidentified Differentially Expressed Genes","volume":"132","author":"Jabbari","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/jid.2012.184","article-title":"Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis","volume":"132","author":"Li","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1101\/gr.137323.112","article-title":"Annotation of functional variation in personal genomes using RegulomeDB","volume":"22","author":"Boyle","year":"2012","journal-title":"Genome Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gkr917","article-title":"HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants","volume":"40","author":"Ward","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"Consortium","year":"2020","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1126\/science.1246949","article-title":"Innate Immune Activity Conditions the Effect of Regulatory Variants upon Monocyte Gene Expression","volume":"343","author":"Fairfax","year":"2014","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ajhg.2010.10.024","article-title":"Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals","volume":"87","author":"Ding","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-016-1142-6","article-title":"Integrated genome-wide analysis of expression quantitative trait loci aids interpretation of genomic association studies","volume":"18","author":"Joehanes","year":"2017","journal-title":"Genome Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression","volume":"175","author":"Schmiedel","year":"2018","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jid.2021.01.015","article-title":"Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits","volume":"141","author":"Shi","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1101\/gr.175034.114","article-title":"Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C","volume":"24","author":"Dryden","year":"2014","journal-title":"Genome Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ng.3286","article-title":"Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C","volume":"47","author":"Mifsud","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Burren, O.S., Rubio Garc\u00eda, A., Javierre, B.M., Rainbow, D.B., Cairns, J., Cooper, N.J., Lambourne, J.J., Schofield, E., Castro Dopico, X., and Ferreira, R.C. (2017). Chromosome contacts in activated T cells identify autoimmune disease candidate genes. Genome Biol., 18.","DOI":"10.1186\/s13059-017-1285-0"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/19491034.2017.1389365","article-title":"Recent evidence that TADs and chromatin loops are dynamic structures","volume":"9","author":"Hansen","year":"2017","journal-title":"Nucleus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/ng.3935","article-title":"Lineage-specific dynamic and pre-established enhancer\u2013promoter contacts cooperate in terminal differentiation","volume":"49","author":"Rubin","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-12-411637-5.00004-4","article-title":"Chapter Four\u2014Detecting DNA\u2013Protein Interactions in Living Cells\u2014ChIP Approach","volume":"Volume 91","author":"Donev","year":"2013","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature23875","article-title":"Discovery of stimula-tion-responsive immune enhancers with CRISPR activation","volume":"549","author":"Simeonov","year":"2017","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Reali, E., and Ferrari, D. (2023). From the Skin to Distant Sites: T Cells in Psoriatic Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115707"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Vi\u010di\u0107, M., Ka\u0161telan, M., Brajac, I., Soto\u0161ek, V., and Massari, L.P. (2021). Current Concepts of Psoriasis Immunopathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111574"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Calautti, E., Avalle, L., and Poli, V. (2018). Psoriasis: A STAT3-Centric View. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010171"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Pso-riasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Madonna, S., Girolomoni, G., Dinarello, C.A., and Albanesi, C. (2019). The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133318"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36\u03b3 Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s13238-018-0505-z","article-title":"IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis","volume":"9","author":"Hou","year":"2018","journal-title":"Protein Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/1346-8138.15184","article-title":"Dendritic cells: The driver of psoriasis","volume":"47","author":"Wang","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a Expression Defines Tis-sue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"618897","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of Skin Resident Memory T Cells","volume":"11","author":"Tokura","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"788940","DOI":"10.3389\/fimmu.2021.788940","article-title":"The Role of Helper T Cells in Psoriasis","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1767","article-title":"Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells","volume":"10","author":"Duhen","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3389\/fimmu.2019.01865","article-title":"IL-21 Induces an Imbalance of Th17\/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients","volume":"10","author":"Shi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A Critical Role of the IL-1\u03b2-IL-1R Signaling Pathway in Skin In-flammation and Psoriasis Pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/eji.201545883","article-title":"Dermal IL-17-producing \u03b3\u03b4 T cells establish long-lived memory in the skin","volume":"45","author":"Hartwig","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fimmu.2020.00242","article-title":"Innate Lymphocytes in Psoriasis","volume":"11","author":"Polese","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00281-019-00740-9","article-title":"The role of invariant T cells in inflammation of the skin and airways","volume":"41","author":"Yip","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/eji.202048645","article-title":"Interleukin-17 producing mucosal associated invariant T cells\u2014Emerging players in chronic inflammatory diseases?","volume":"50","author":"Pisarska","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s11596-006-0634-0","article-title":"Expression of plasmacytoid dendritic cells, IRF-7, IFN-alpha mRNA in the lesions of psoriasis vulgaris","volume":"26","author":"Chen","year":"2006","journal-title":"J. Huazhong Univ. Sci. Technolog Med. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-\u03b1 production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1346-8138.12367","article-title":"Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: A role for interferon-alpha in dendritic cell activation by imiquimod","volume":"41","author":"Ueyama","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., and Romanelli, M. (2018). Scanning the Immunopathogenesis of Psoriasis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010179"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3683","article-title":"The origins and functions of dendritic cells and macrophages in the skin","volume":"14","author":"Malissen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 Family: Room for Discovery","volume":"50","author":"Wojno","year":"2019","journal-title":"Immunity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator\u2013controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sawyer, L.M., Malottki, K., Sabry-Grant, C., Yasmeen, N., Wright, E., Sohrt, A., Borg, E., and Warren, R.B. (2019). Assessing the relative efficacy of inter-leukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220868"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref_103","unstructured":"NICE (2024, January 09). NIfHaCE. Psoriasis 2022. Available online: https:\/\/cks.nice.org.uk\/topics\/psoriasis\/management\/trunk-limbs\/."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic Treatment of Psoriasis with JAK Inhibitors: A Review","volume":"10","author":"Hansen","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2013","journal-title":"Int. Immunol."},{"key":"ref_106","first-page":"1","article-title":"Discovery of a novel ROR\u03b3 antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3389\/fimmu.2018.01210","article-title":"Transcription Factor Retinoid-Related Orphan Receptor \u03b3t: A Promising Target for the Treatment of Psoriasis","volume":"9","author":"Tang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-\u03baB: An essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/icb.2015.77","article-title":"TLR3 drives IRF6-dependent IL-23p19 expression and p19\/EBI3 heterodimer formation in keratinocytes","volume":"93","author":"Ramnath","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/jid.2012.280","article-title":"Genetic Association with ERAP1 in Psoriasis Is Confined to Disease Onset after Puberty and Not Dependent on HLA-C*06","volume":"133","author":"Lysell","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: Defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the ran-domized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis\u2014Head-to-head trials comparing dif-ferent biologics in psoriasis treatment","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a ran-domized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","article-title":"Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment","volume":"151","author":"Menting","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13555-022-00693-2","article-title":"Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago","volume":"12","author":"Paradela","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach","volume":"35","author":"Tsakok","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B.J., and Wine, Y. (2020). The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01951"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn\u2019s Disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"H\u00e4ssler, S., Bachelet, D., Duhaze, J., Szely, N., Gleizes, A., Abina, S.H.-B., Aktas, O., Auer, M., Avouac, J., and Birchler, M. (2020). Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLOS Med., 17.","DOI":"10.1371\/journal.pmed.1003348"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Liu, M., Degner, J., Davis, J.W., Idler, K.B., Nader, A., Mostafa, N.M., and Waring, J.F. (2018). Identification of HLA-DRB1 association to ada-limumab immunogenicity. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195325"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Berna-Rico, E., Perez-Bootello, J., de Aragon, C.A.-J., and Gonzalez-Cantero, A. (2023). Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129850"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.16705","article-title":"Secukinumab shows high efficacy irre-spective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis","volume":"20","author":"Galluzzo","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_131","first-page":"112","article-title":"Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: Results from a multicentre study of four European psoriasis cohorts","volume":"34","author":"Reek","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28, post hoc analysis through 64 weeks from reSURFACE 1 trial","volume":"35","author":"Warren","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2019.01.035","article-title":"Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study","volume":"88","author":"Chiu","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: A retrospective cohort study in 77 patients","volume":"31","author":"Regnault","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.15292","article-title":"The Japanese Ixekizumab Study Group Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: Impact of treatment withdrawal and retreatment of ixekizumab","volume":"33","author":"Umezawa","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J. Dermatol. Treat."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.23736\/S0392-0488.18.06156-4","article-title":"A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study)","volume":"154","author":"Stinco","year":"2019","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ajhg.2023.08.010","article-title":"Response to anti-IL17 therapy in inflam-matory disease is not strongly impacted by genetic background","volume":"110","author":"Zhang","year":"2023","journal-title":"Am. J. Hum. Genet."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/5\/548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:39:02Z","timestamp":1760107142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/5\/548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":141,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["biom14050548"],"URL":"https:\/\/doi.org\/10.3390\/biom14050548","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]}}}